Literature DB >> 34669043

Evaluating the tendencies of community practitioners who actively practice in child and adolescent psychiatry to diagnose and treat DSM-5 attenuated psychotic syndrome.

Helin Yilmaz Kafali1, Mireia Solerdelcoll2,3, Lena Vujinovic4, Dmytro Martsenkovskyi5,6, Sewanu Awhangansi7, Camille Noel8,9, Emre Bora10,11, Celso Arango12.   

Abstract

The detection of individuals at clinical ultra-high risk for psychosis (CHR-P) may be a key limiting step for early interventions, and there is some uncertainty regarding the true clinical reliability of the CHR-P states. The aim of this study was to explore how practitioners who were in the direct treatment of children with psychiatric disorders [child psychiatry specialists/trainees (n = 227, n = 131), adult psychiatrists (n = 27), and child neurologists (n = 2)] perceive the DSM-5-Attenuated Psychosis Syndrome (DSM-5-APS), and their clinical routine practice in the treatment of it. Three vignettes describing fictional cases presented with symptoms of either DSM-5-Schizophrenia, DSM-5-APS, and no psychotic symptoms were created. We asked these practitioners to apply a DSM-5 diagnosis and to choose appropriate treatment(s) for these vignettes. Of the responders, 43% correctly diagnosed the APS vignette, whereas 37.4% mentioned that it had a full-blown psychotic episode. Regarding the therapeutic approach for the APS vignette, 72.1% of all practitioners chose a psychopharmacological intervention and 32% individual psychotherapy. This study showed that the diagnostic inter-rater reliability of the DSM-5-APS among child/adolescent mental health practitioners was consistent with the results from the DSM-5 field trials (Kappa = 0.46). Moreover, almost three in four practitioners endorsed psychopharmacological intervention as a treatment option for the DSM-5-APS case. The lack of evidence of psychopharmacological interventions in CHR-P situations emphasizes that the least harmful interventions should be recommended. Thus, our findings indicated a need for raising awareness regarding the CHR-P paradigm and its treatment as well as the development of solid guidelines that can be implemented in clinical practice.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Entities:  

Keywords:  Adolescence; Attenuated psychotic syndrome; Child psychiatry; Clinical high risk; Psychosis; Schizophrenia spectrum disorder

Mesh:

Year:  2021        PMID: 34669043     DOI: 10.1007/s00787-021-01897-1

Source DB:  PubMed          Journal:  Eur Child Adolesc Psychiatry        ISSN: 1018-8827            Impact factor:   5.349


  21 in total

1.  Neurodevelopmental origin of cognitive impairment in schizophrenia.

Authors:  E Bora
Journal:  Psychol Med       Date:  2014-05-30       Impact factor: 7.723

2.  EPA guidance on the early intervention in clinical high risk states of psychoses.

Authors:  S J Schmidt; F Schultze-Lutter; B G Schimmelmann; N P Maric; R K R Salokangas; A Riecher-Rössler; M van der Gaag; A Meneghelli; M Nordentoft; M Marshall; A Morrison; A Raballo; J Klosterkötter; S Ruhrmann
Journal:  Eur Psychiatry       Date:  2015-03-03       Impact factor: 5.361

Review 3.  Altering the course of schizophrenia: progress and perspectives.

Authors:  Mark J Millan; Annie Andrieux; George Bartzokis; Kristin Cadenhead; Paola Dazzan; Paolo Fusar-Poli; Jürgen Gallinat; Jay Giedd; Dennis R Grayson; Markus Heinrichs; René Kahn; Marie-Odile Krebs; Marion Leboyer; David Lewis; Oscar Marin; Philippe Marin; Andreas Meyer-Lindenberg; Patrick McGorry; Philip McGuire; Michael J Owen; Paul Patterson; Akira Sawa; Michael Spedding; Peter Uhlhaas; Flora Vaccarino; Claes Wahlestedt; Daniel Weinberger
Journal:  Nat Rev Drug Discov       Date:  2016-03-04       Impact factor: 84.694

4.  Practitioner perceptions of attenuated psychosis syndrome.

Authors:  Elizabeth Jacobs; Emily Kline; Jason Schiffman
Journal:  Schizophr Res       Date:  2011-07-20       Impact factor: 4.939

5.  Quality of life in individuals with attenuated psychotic symptoms: Possible role of anxiety, depressive symptoms, and socio-cognitive impairments.

Authors:  Tsutomu Takahashi; Yuko Higuchi; Yuko Komori; Shimako Nishiyama; Mihoko Nakamura; Daiki Sasabayashi; Yumiko Nishikawa; Tomiki Sumiyoshi; Michio Suzuki
Journal:  Psychiatry Res       Date:  2017-08-16       Impact factor: 3.222

Review 6.  Schizophrenia.

Authors:  Jim van Os; Shitij Kapur
Journal:  Lancet       Date:  2009-08-22       Impact factor: 79.321

7.  Defining treatment as usual for attenuated psychosis syndrome: a survey of community practitioners.

Authors:  Elizabeth Jacobs; Emily Kline; Jason Schiffman
Journal:  Psychiatr Serv       Date:  2012-12       Impact factor: 3.084

Review 8.  Annual Research Review: Prevention of psychosis in adolescents - systematic review and meta-analysis of advances in detection, prognosis and intervention.

Authors:  Ana Catalan; Gonzalo Salazar de Pablo; Julio Vaquerizo Serrano; Pierluca Mosillo; Helen Baldwin; Aranzazu Fernández-Rivas; Carmen Moreno; Celso Arango; Christoph U Correll; Ilaria Bonoldi; Paolo Fusar-Poli
Journal:  J Child Psychol Psychiatry       Date:  2020-09-14       Impact factor: 8.982

9.  Early intervention in psychosis: concepts, evidence and future directions.

Authors:  Patrick D McGorry; Eóin Killackey; Alison Yung
Journal:  World Psychiatry       Date:  2008-10       Impact factor: 49.548

10.  Real-world effectiveness of antipsychotic treatment in psychosis prevention in a 3-year cohort of 517 individuals at clinical high risk from the SHARP (ShangHai At Risk for Psychosis).

Authors:  TianHong Zhang; LiHua Xu; XiaoChen Tang; YanYan Wei; Qiang Hu; YeGang Hu; HuiRu Cui; YingYing Tang; Li Hui; ChunBo Li; LiPing Cao; Zheng Lu; JiJun Wang
Journal:  Aust N Z J Psychiatry       Date:  2020-05-21       Impact factor: 5.744

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.